ASH 2019

Area: Hematology

Location: Orlando, United States

Date: December 7 to December 10


Search in Scientific Content:
Date
Filters:
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
Primary An
2:48

Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Novelties
11:01

Novelties on the treatment of non-Hodgkin lymphoma

Presenter: Umberto Vitolo
Hematology
Inhibition
4:46

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
4:41

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
LBA-5 Vali
3:58

LBA-5 Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: Robert M. Rifkin
Hematology
Clinical I
7:02

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Presenter: Wyndham Wilson
Hematology
Special Ed
4:53

Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism

Presenter: Adam Cuker
Hematology
Novelties
6:35

Novelties on the treatment of follicular lymphoma

Presenter: Kai Hübel
Hematology
A Multicen
3:39

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Presenter: Kerry A Rogers
Hematology
Evaluating
3:01

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Presenter: Vip Viprakasit
Hematology
Treatment
3:52

Treatment of multiple myeloma

Presenter: Shaji Kumar
Hematology
Phase II T
3:10

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Presenter: Leon Bernal-Mizrachi
Hematology
Targeting
3:43

Targeting Apoptosis in Myeloma

Presenter: Wee-Joo Chng
Hematology
Lower Risk...
7:32

Lower Risk MDS – Transfusion Dependence

Presenter: Agnieszka Pluta
Hematology
Rivaroxaba
4:24

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response EvaluationClinically Relevant Abstract

Presenter: Guy Young
Hematology
RRMM and i
4:54

RRMM and immunomodulators

Presenter: Dominik Dytfeld
Hematology

EHA 2020

2020-06-11 - 2020-06-21
Online, Virtual

ESH 2020

2020-05-29 - 2020-06-01
Online, Virtual

EHA 2019

2019-06-13 - 2019-06-16
Amsterdam, Netherlands

EMMA 2019

2019-01-31 - 2019-02-02
Vienna, Austria

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden

ASH 2017

2017-12-09 - 2017-12-12
Atlanta, United States

EHA 2017

2017-06-22 - 2017-06-25
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland